Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.74 |
| ▸ | DRD3 | P35462 | 11/20 | 0.69 |
| ▸ | DRD2 | P14416 | 6/20 | 0.69 |
| ▸ | HRH1 | P35367 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.64 |
| ▸ | HTR1A | P08908 | 1/20 | 0.64 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.64 |
| ▸ | HTR2B | P41595 | 1/20 | 0.64 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.64 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6865289 | 0.89 | HRH4 (0.78) | HRH4DRD3DRD2HRH1POLB | |
| SCHEMBL2345954 | 0.88 | HRH4 (0.76) | HRH4DRD3DRD2POLBSMN1; SMN2 | |
| SCHEMBL29944207 | 0.88 | HRH4 (0.76) | HRH4DRD3DRD2POLBSMN1; SMN2 | |
| SCHEMBL2350768 | 0.86 | HRH4 (0.78) | HRH4DRD3DRD2POLBSMN1; SMN2 | |
| SCHEMBL6141947 | 0.86 | AKR1C3 (0.67) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL605483 | 0.85 | HRH4 (1.00) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL605555 | 0.85 | HRH4 (0.77) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL24588431 | 0.85 | HRH4 (0.69) | HRH4DRD3DRD2HRH1ADRB1 | |
| SCHEMBL603454 | 0.84 | HRH4 (1.00) | HRH4DRD3DRD2HRH1POLB | |
| SCHEMBL6383382 | 0.84 | HRH4 (0.72) | HRH4DRD3DRD2HRH1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-1373204-B1 | HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICALS INC (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2382013-B1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-07-13 | — | — | EP | disclosed |
| US-20150176010-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | SENSORION (FR) | 2015-06-25 | — | — | US | disclosed |
| WO-2010072829-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS. | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-07-01 | — | — | WO | disclosed |
| EP-2201982-A1 | Histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | DUNFORD PAUL J | 2009-03-12 | — | — | US | disclosed |
| EP-2010177-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120690-A2 | COMBINATION HISTAMINE H1R AND H4R ANTAGONIST THERAPY FOR TREATING PRURITUS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1551406-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-07-13 | — | — | EP | disclosed |
| US-20050085487-A1 | Heterocyclic compounds | CARRUTHERS NICHOLAS I (US) | 2005-04-21 | — | — | US | disclosed |
| WO-2004022061-A1 | USE OF INDOLYL DERIVATIVES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT ALLERGIC RHINITIS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085487-A1 | Heterocyclic compounds | AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NQO1 | HRH4 1501/4885DRD3 995/4885DRD2 1224/4885 |
| US-20090069343-A1 | Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus | HRH4, HRH2, HRH3 | HRH4 1/4885DRD3 593/4885DRD2 249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.